Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy

Pathology

Volumn 48, Issue 2, 2016, Pages 177-187

  Lee, Nayoung ^a   Zakka, Labib R ^b   Mihm, Martin C ^b   Schatton, Tobias ^b,c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

checkpoint blockade; CTLA 4; immunomodulation; immunotherapy; melanoma; PD 1; TIL; tumour immune escape; Tumour infiltrating lymphocyte

Indexed keywords

ADAPTIVE IMMUNITY; ARTICLE; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; HUMAN; IMMUNOMODULATION; MELANOMA; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PHENOTYPE; PREDICTIVE VALUE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; CLASSIFICATION; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PROGNOSIS; SKIN NEOPLASMS; T LYMPHOCYTE SUBPOPULATION;

HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; PROGNOSIS; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS;

EID: 84975455856     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1016/j.pathol.2015.12.006     Document Type: Article

References (121)

1. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill Cancer-related inflammation Nature 454 2008 436 444
2. L. Zhang, J.R. Conejo-Garcia, D. Katsaros, and et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N Engl J Med 348 2003 203 213
3. F. Pages, A. Berger, M. Camus, and et al. Effector memory T cells, early metastasis, and survival in colorectal cancer N Engl J Med 353 2005 2654 2666
4. W.H. Clark Jr., L. From, E.A. Bernardino, and M.C. Mihm The histogenesis and biologic behavior of primary human malignant melanomas of the skin Cancer Res 29 1969 705 727
5. P. Hersey, C. Bindon, A. Edwards, E. Murray, G. Phillips, and W.H. McCarthy Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin 2 Int J Cancer 28 1981 695 703
6. W.H. Clark Jr., D.E. Elder, D. Guerry 4th, and et al. Model predicting survival in stage I melanoma based on tumor progression J Natl Cancer Inst 81 1989 1893 1904
7. C.G. Clemente, M.C. Mihm Jr., R. Bufalino, S. Zurrida, P. Collini, and N. Cascinelli Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma Cancer 77 1996 1303 1310
8. M.C. Mihm Jr., C.G. Clemente, and N. Cascinelli Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response Lab Invest 74 1996 43 47
9. S.A. Rosenberg, B.S. Packard, P.M. Aebersold, and et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report N Engl J Med 319 1988 1676 1680
10. K.J. Busam, C.R. Antonescu, A.A. Marghoob, and et al. Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma. A study of interobserver agreement Am J Clin Pathol 115 2001 856 860
11. U.N. Rao, S.J. Lee, W. Luo, M.C. Mihm Jr., and J.M. Kirkwood Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials Am J Clin Pathol 133 2010 646 653
12. F. Azimi, R.A. Scolyer, P. Rumcheva, and et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma J Clin Oncol 30 2012 2678 2683
13. T.E. Larsen, and T.H. Grude A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 3. The relation between the tumour-associated lymphocyte infiltration and age and sex, tumour cell type, pigmentation, cellular atypia, mitotic count, depth of invasion, ulceration, tumour type and prognosis Acta Pathol Microbiol Scand A 86A 1978 523 530
14. C.L. Day Jr., A.J. Sober, A.W. Kopf, and et al. A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease Ann Surg 193 1981 436 440
15. A.L. Burton, B.A. Roach, M.P. Mays, and et al. Prognostic significance of tumor infiltrating lymphocytes in melanoma Am Surg 77 2011 188 192
16. R.L. Barnhill, J.A. Fine, G.C. Roush, and M. Berwick Predicting five-year outcome for patients with cutaneous melanoma in a population-based study Cancer 78 1996 427 432
17. M. Thorn, F. Ponten, R. Bergstrom, P. Sparen, and H.O. Adami Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden J Natl Cancer Inst 86 1994 761 769
18. E. Mansson-Brahme, J. Carstensen, K. Erhardt, B. Lagerlöf, U. Ringborg, and L.E. Rutqvist Prognostic factors in thin cutaneous malignant melanoma Cancer 73 1994 2324 2332
19. P.A. Gimotty, P. Van Belle, D.E. Elder, and et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma J Clin Oncol 23 2005 8048 8056
20. R.J. Tuthill, J.M. Unger, P.Y. Liu, and et al. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model Am J Clin Pathol 118 2002 504 511
21. I.S. van Houdt, B.J. Sluijter, L.M. Moesbergen, and et al. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression Int J Cancer 123 2008 609 615
22. B. Krynitz, B.L. Rozell, J. Lyth, K.E. Smedby, and B. Lindelof Cutaneous malignant melanoma in the Swedish organ transplantation cohort: a study of clinicopathological characteristics and mortality J Am Acad Dermatol 73 2015 106 113
23. L.L. Kruper, F.R. Spitz, B.J. Czerniecki, and et al. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma Cancer 107 2006 2436 2445
24. R.C. Taylor, A. Patel, K.S. Panageas, K.J. Busam, and M.S. Brady Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma J Clin Oncol 25 2007 869 875
25. M. Mandala, G.L. Imberti, D. Piazzalunga, and et al. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database Eur J Cancer 45 2009 2537 2545
26. P. Donizy, M. Kaczorowski, A. Halon, M. Leskiewicz, C. Kozyra, and R. Matkowski Paucity of tumor-infiltrating lymphocytes is an unfavorable prognosticator and predicts lymph node metastases in cutaneous melanoma patients Anticancer Res 35 2015 351 358
27. F. Pandolfi, L.A. Boyle, L. Trentin, J.T. Kurnick, K.J. Isselbacher, and S. Gattoni-Celli Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition Cancer Res 51 1991 3164 3170
28. M.Y. Mapara, and M. Sykes Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance J Clin Oncol 22 2004 1136 1151
29. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 2012 252 264
30. S.A. Rosenberg A new era for cancer immunotherapy based on the genes that encode cancer antigens Immunity 10 1999 281 287
31. T.N. Schumacher, and R.D. Schreiber Neoantigens in cancer immunotherapy Science 348 2015 69 74
32. H.T. Khong, Q.J. Wang, and S.A. Rosenberg Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression J Immunother 27 2004 184 190
33. M.J. Maeurer, S.M. Gollin, D. Martin, and et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen J Clin Invest 98 1996 1633 1641
34. A.D. Boiko, O.V. Razorenova, M. van de Rijn, and et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271 Nature 466 2010 133 137
35. T. Schatton, U. Schütte, N.Y. Frank, and et al. Modulation of T-cell activation by malignant melanoma initiating cells Cancer Res 70 2010 697 708
36. T. Schatton, G.F. Murphy, N.Y. Frank, and et al. Identification of cells initiating human melanomas Nature 451 2008 345 349
37. R. Solana, J.G. Casado, E. Delgado, and et al. Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands Cancer Immunol Immunother 56 2007 101 109
38. M. Hahne, D. Rimoldi, M. Schröter, and et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape Science 274 1996 1363 1366
39. L. Gorelik, and R.A. Flavell Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells Nat Med 7 2001 1118 1122
40. A. Nicolaou, S.E. Estdale, M. Tsatmali, D.P. Herrero, and A.J. Thody Prostaglandin production by melanocytic cells and the effect of alpha-melanocyte stimulating hormone FEBS Lett 570 2004 223 226
41. K.A. Hogquist, T.A. Baldwin, and S.C. Jameson Central tolerance: learning self-control in the thymus Nat Rev Immunol 5 2005 772 782
42. E.M. Sotomayor, I. Borrello, F.M. Rattis, and et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression Blood 98 2001 1070 1077
43. D. Guerry 4th, M.A. Alexander, M.F. Herlyn, and et al. HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes J Clin Invest 73 1984 267 271
44. J.C. Becker, T. Brabletz, C. Czerny, C. Termeer, and E.B. Brocker Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma Int Immunol 5 1993 1501 1508
45. F. Hirano, K. Kaneko, H. Tamura, and et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Res 65 2005 1089 1096
46. H. Dong, S.E. Strome, D.R. Salomao, and et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 2002 793 800
47. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
48. J.F. Jacobs, S. Nierkens, C.G. Figdor, I.J. de Vries, and G.J. Adema Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 13 2012 e32 42
49. K. Wing, Y. Onishi, P. Prieto-Martin, and et al. CTLA-4 control over Foxp3+ regulatory T cell function Science 322 2008 271 275
50. C. Jandus, G. Bioley, D.E. Speiser, and et al. Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood Cancer Immunol Immunother 57 2008 1795 1805
51. L. Vence, A.K. Palucka, J.W. Fay, and et al. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma Proc Natl Acad Sci USA 104 2007 20884 20889
52. E.J. Wherry T cell exhaustion Nat Immunol 12 2011 492 499
53. L. Baitsch, P. Baumgaertner, E. Devevre, and et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients J Clin Invest 121 2011 2350 2360
54. F.S. Hodi, S.J. O'Day, D.F. McDermott, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
55. S.L. Topalian, F.S. Hodi, J.R. Brahmer, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
56. N. Patsoukis, K. Bardhan, P. Chatterjee, and et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation Nat Commun 6 2015 6692
57. P.C. Ho, J.D. Bihuniak, A.N. Macintyre, and et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses Cell 162 2015 1217 1228
58. C.H. Chang, J. Qiu, D. O'Sullivan, and et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression Cell 162 2015 1229 1241
59. S. Kleffel, C. Posch, S.R. Barthel, and et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth Cell 162 2015 1242 1256
60. T. Schatton, R.A. Scolyer, J.F. Thompson, and M.C. Mihm Jr. Tumor-infiltrating lymphocytes and their significance in melanoma prognosis Methods Mol Biol 1102 2014 287 324
61. N.P. Restifo, M.E. Dudley, and S.A. Rosenberg Adoptive immunotherapy for cancer: harnessing the T cell response Nat Rev Immunol 12 2012 269 281
62. N.H. Segal, D.W. Parsons, K.S. Peggs, and et al. Epitope landscape in breast and colorectal cancer Cancer Res 68 2008 889 892
63. V. Boisguerin, J.C. Castle, M. Loewer, and et al. Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside Br J Cancer 111 2013 1469 1475
64. R.H. Vonderheide, and K.L. Nathanson Immunotherapy at large: the road to personalized cancer vaccines Nat Med 19 2013 1098 1100
65. C.S. Hinrichs, and S.A. Rosenberg Exploiting the curative potential of adoptive T-cell therapy for cancer Immunol Rev 257 2014 56 71
66. A. Khammari, A.C. Knol, J.M. Nguyen, and et al. Adoptive TIL transfer in the adjuvant setting for melanoma: long-term patient survival J Immunol Res 2014 2014 186212
67. C.L. Batlevi, E. Matsuki, R.J. Brentjens, and A. Younes Novel immunotherapies in lymphoid malignancies Nat Rev Clin Oncol 2015 Nov 3: [Epub ahead of print]
68. K. Itoh, A.B. Tilden, and C.M. Balch Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas Cancer Res 46 1986 3011 3017
69. M.B. Atkins, M.T. Lotze, J.P. Dutcher, and et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 1999 2105 2116
70. D.J. Schwartzentruber, D.H. Lawson, J.M. Richards, and et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma N Engl J Med 364 2011 2119 2127
71. J.T. Rubin, L.J. Elwood, S.A. Rosenberg, and M.T. Lotze Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans Cancer Res 49 1989 7086 7092
72. M. Sabatino, S. Kim-Schulze, M.C. Panelli, and et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy J Clin Oncol 27 2009 2645 2652
73. R.E. Royal, S.M. Steinberg, R.S. Krouse, and et al. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma Cancer J Sci Am 2 1996 91 98
74. M. Ahmadzadeh, and S.A. Rosenberg IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients Blood 107 2006 2409 2414
75. S.J. Moschos, H.D. Edington, S.R. Land, and et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses J Clin Oncol 24 2006 3164 3171
76. A.A. Tarhini, J. Cherian, S.J. Moschos, and et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma J Clin Oncol 30 2012 322 328
77. E.J. Wherry, and M. Kurachi Molecular and cellular insights into T cell exhaustion Nat Rev Immunol 15 2015 486 499
78. R.J. Greenwald, G.J. Freeman, and A.H. Sharpe The B7 family revisited Annu Rev Immunol 23 2005 515 548
79. D.R. Leach, M.F. Krummel, and J.P. Allison Enhancement of antitumor immunity by CTLA-4 blockade Science 271 1996 1734 1736
80. C. Robert, L. Thomas, I. Bondarenko, and et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
81. D. Schadendorf, F.S. Hodi, C. Robert, and et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma J Clin Oncol 33 2015 1889 1894
82. S. Kitano, T. Tsuji, C. Liu, and et al. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients Cancer Immunol Res 1 2013 235 244
83. J.S. Weber, O. Hamid, S.D. Chasalow, and et al. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma J Immunother 35 2012 89 97
84. Z.A. Cooper, V.R. Juneja, P.T. Sage, and et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade Cancer Immunol Res 2 2014 643 654
85. F.S. Hodi, M. Butler, D.A. Oble, and et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients Proc Natl Acad Sci USA 105 2008 3005 3010
86. W. Wang, D. Yu, A.A. Sarnaik, and et al. Biomarkers on melanoma patient T cells associated with ipilimumab treatment J Transl Med 10 2012 146
87. A.A. Tarhini, H. Edington, L.H. Butterfield, and et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab PLoS One 9 2014 e87705
88. L. Robert, J. Tsoi, X. Wang, and et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire Clin Cancer Res 20 2014 2424 2432
89. A. Ribas, F.S. Hodi, M. Callahan, C. Konto, and J. Wolchok Hepatotoxicity with combination of vemurafenib and ipilimumab N Engl J Med 368 2013 1365 1366
90. T. Fu, Q. He, and P. Sharma The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy Cancer Res 71 2011 5445 5454
91. A. Snyder, V. Makarov, T. Merghoub, and et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma N Engl J Med 371 2014 2189 2199
92. E.M. Van Allen, D. Miao, B. Schilling, and et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma Science 350 2015 207 211
93. M.A. Postow, M.K. Callahan, and J.D. Wolchok Immune checkpoint blockade in cancer therapy J Clin Oncol 33 2015 1974 1982
94. L.M. Francisco, P.T. Sage, and A.H. Sharpe The PD-1 pathway in tolerance and autoimmunity Immunol Rev 236 2010 219 242
95. Y. Latchman, C.R. Wood, T. Chernova, and et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nat Immunol 2 2001 261 268
96. S. Derks, K.S. Nason, X. Liao, and et al. Epithelial PD-L2 expression marks Barrett's esophagus and esophageal adenocarcinoma Cancer Immunol Res 3 2015 1123 1129
97. S.L. Topalian, C.G. Drake, and D.M. Pardoll Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity Curr Opin Immunol 24 2012 207 212
98. A.T. Parsa, J.S. Waldron, A. Panner, and et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma Nat Med 13 2007 84 88
99. M. Ahmadzadeh, L.A. Johnson, B. Heemskerk, and et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired Blood 114 2009 1537 1544
100. J. Fourcade, Z. Sun, M. Benallaoua, and et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients J Exp Med 207 2010 2175 2186
101. A. Gros, P.F. Robbins, X. Yao, and et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors J Clin Invest 124 2014 2246 2259
102. N. Rodic, R.A. Anders, J.R. Eshleman, and et al. PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation Cancer Immunol Res 3 2015 110 115
103. J.M. Taube, R.A. Anders, G.D. Young, and et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci Transl Med 4 2012 127 137
104. D. Massi, D. Brusa, B. Merelli, and et al. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics Ann Oncol 25 2014 2433 2442
105. K.M. Mahoney, P.D. Rennert, and G.J. Freeman Combination cancer immunotherapy and new immunomodulatory targets Nat Rev Drug Discov 14 2015 561 584
106. J.S. Weber, S.P. D'Angelo, D. Minor, and et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Lancet Oncol 16 2015 375 384
107. J. Larkin, F.S. Hodi, and J.D. Wolchok Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 2015 1270 1271
108. C. Robert, J. Schachter, G.V. Long, and et al. Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 372 2015 2521 2532
109. M.A. Postow, J. Chesney, A.C. Pavlick, and et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N Engl J Med 372 2015 2006 2017
110. H. Borghaei, L. Paz-Ares, L. Horn, and et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 373 2015 1627 1639
111. C. Twyman-Saint Victor, A.J. Rech, A. Maity, and et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer Nature 520 2015 373 377
112. J.D. Wolchok, H. Kluger, M.K. Callahan, and et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
113. D.T. Frederick, A. Piris, A.P. Cogdill, and et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma Clin Cancer Res 19 2013 1225 1231
114. Z.A. Cooper, D.T. Frederick, V.R. Juneja, and et al. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes Oncoimmunology 2 2013 e26615
115. X. Jiang, J. Zhou, A. Giobbie-Hurder, J. Wargo, and F.S. Hodi The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition Clin Cancer Res 19 2013 598 609
116. J.M. Taube, A. Klein, J.R. Brahmer, and et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy Clin Cancer Res 20 2014 5064 5074
117. R.S. Herbst, J.C. Soria, M. Kowanetz, and et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 2014 563 567
118. P.C. Tumeh, C.L. Harview, J.H. Yearley, and et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance Nature 515 2014 568 571
119. M.M. Gubin, X. Zhang, H. Schuster, and et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens Nature 515 2014 577 581
120. N.A. Rizvi, M.D. Hellmann, A. Snyder, and et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer Science 348 2015 124 128
121. M. Yadav, S. Jhunjhunwala, Q.T. Phung, and et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing Nature 515 2014 572 576